Phase II trial of the anti-GD2 monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma

Journal of Clinical Oncology

Volumn 19, Issue 22, 2001, Pages 4189-4194

  Kushner, B H ^a   Kramer, K ^a   Cheung, N K V ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXYCYCLINE; ETOPOSIDE; GANGLIOSIDE GD2; IFOSFAMIDE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 3F8; OPIATE AGONIST; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RETINOIC ACID; UNCLASSIFIED DRUG; VINCRISTINE;

ADOLESCENT; ANTIBODY TITER; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RECURRENCE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; NEUROBLASTOMA; OUTPATIENT CARE; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; RECURRENT DISEASE;

EID: 0035890643     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.22.4189     Document Type: Article

References (37)

1. Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells
2. D2 in tumor tissues and sera of neuroblastoma
3. D2 loss following monoclonal antibody therapy is rare in neuroblastoma
4. Radioimmunodetection of neuroblastoma with iodine-131-3F8: Correlation with biopsy, iodine-131-metaiodobenzylguanidine and standard diagnostic modalities
5. Eradication of neuroblastoma cells in vitro by monoclonal antibody and human complement: Method for purging autologous bone marrow
6. Interleukin-2 enhancement of monoclonal antibody-mediated cellular cytotoxicity against human melanoma
7. Antibody-dependent antitumor cytotoxicity by human monocytes cultured with recombinant macrophage colony-stimulating factor
8. GM-CSF enhances 3F8 monoclonal antibody-dependent cellular cytotoxicity against human melanoma and neuroblastoma
9. Decay-accelerating factor protects human tumor cells from complement-mediated cytotoxicity in vitro
10. D2 specific monoclonal antibody 3F8: A phase I study in patients with neuroblastoma and malignant melanoma
11. 3F8 monoclonal antibody treatment of patients with stage 4 neuroblastoma: A phase II study
12. D2 antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age
13. A phase I/II trial of recombinant granulocyte-macrophage colony-stimulating factor for children with aplastic anemia
14. Therapeutic effects and pharmacokinetics of recombinant human granulocyte-macrophage colony-stimulating factor in childhood cancer patients receiving myelosuppressive chemotherapy
15. D2 antibody on cell-mediated lysis of human neuroblastoma cells
16. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment
17. D2 monoclonal antibodies: Correlation with patient survival
18. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid
19. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor
20. In vitro assessment of the effects of granulocyte-macrophage colony-stimulating factor on primary human tumors and derived lines
21. Hematopoietic colony-stimulating factors: Uses in combination with standard chemotherapeutic regimens and in support of dose intensification
22. An eosinophil-dependent mechanism for the antitumor effect of interleukin 4
23. Interleukin-5, eosinophils, and disease
24. 2 microglobulin on human neuroblastoma cell lines
25. Cell adhesion molecules expression and modulation on human neuroblastoma cells
26. Pharmacokinetics of human granulocyte-macrophage colony-stimulating factor using a sensitive immunoassay
27. Disposition of recombinant human granulocyte-macrophage colony-stimulating factor in patients receiving high-dose chemotherapy and autologous bone marrow support
28. Neutrophil migration is defective during recombinant human granulocyte-macrophage colony-stimulating factor infusion after autologous bone marrow transplantation in human
29. Hyperfractionated low-dose radiotherapy (21 Gy) for high-risk neuroblastoma after intensive chemotherapy and surgery
30. A phase I study of neuroblastoma with the anti-ganglioside GD 2 antibody 14.G2a
31. Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors
32. A phase I study of human/mouse chimeric anti-ganglioside GD 2 antibody ch14.18 in patients with neuroblastoma
33. A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: A report of the Children's Cancer Group
34. Usefulness of a chimeric anti-GD2 (ch14.18) and GM-CSF for refractory neuroblastoma: A POG phase II study
35. Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch 14.18 in patients with refractory neuroblastoma and osteosarcoma
36. D2 monoclonal antibody (chl4.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: A Children's Cancer Group study
37. D2 monoclonal antibody 3F8 therapy of stage 4 neuroblastoma